A report released by the World Health Organization in 2017 mentioned that about 322 million people suffer from depression worldwide; according to the “2022 National Depression Blue Book”, the number of people suffering from depression in my country is as high as 95 million, but the treatment rate is only 9.5%. As social pressure increases, more and more people have mental health problems, the number of patients with depression continues to increase, and the demand for antidepressants continues to increase. According to Grand View Research, the global antidepressant market size will reach US$60 billion in 2028. At present, although there are many antidepressants available clinically, most drugs still have defects such as slow onset, low efficiency, and even sexual dysfunction and cognitive impairment. Therefore, patients still need more new and effective antidepressants. LPM682000012 is a Class 1 new drug declared by Luye Pharmaceuticals. The indication for clinical trials approved this ...
Recently, Johnson & Johnson announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for its Varipulse pulsed field ablation system for the treatment of drug-refractory paroxysmal atrial fibrillation. After obtaining approval, Johnson & Johnson became the third company in the United States to have PFA technology for the treatment of AFib, joining the ranks of Medtronic and Boston Scientific, and the three-way competition in the PFA market has officially begun. It is understood that the Varipulse pulsed field ablation system consists of the Varipulse ablation catheter and the TRUPULSE generator. Among them, the VARIPULSE ablation catheter was developed based on Johnson & Johnson’s previous mapping catheter LASSO catheter, which is a continuation of the LASSO catheter technology, which further demonstrates Johnson & Johnson’s deep technical reserves in the catheter field. The Varipulse ablation catheter has 10 electrodes on the ring tip, and the ring tip ...
Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has been severely warned by shareholders due to poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared: If the company’s performance cannot be improved, Deepak Nath will be dismissed, and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and advanced wound management. At present, Smith & Nephew ...
On the evening of November 12, BeiGene released its 2024 third quarter US stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continued to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. The US stock financial report shows that BeiGene’s financial situation continues to improve, with total revenue of US$1.002 billion this ...
In 2024, 207 varieties passed/are deemed to have passed the consistency evaluation in October, involving 203 companies (counted as group companies), of which 47 companies passed multiple varieties, and Zhengda Tianqing Pharmaceutical Group Co., Ltd. had the largest number of varieties passed. Chiatai Tianqing ranked first in the “number of varieties passed by the company” 1. Overall situation In October, a total of 207 varieties passed/are deemed to have passed the consistency evaluation: 151 varieties were deemed to have passed the consistency evaluation when they were launched as newly registered classified generic drugs; 59 varieties passed the evaluation with supplementary applications for generic drug consistency evaluation, an increase of 20 varieties compared to September. According to the statistics of the approval documents for marketed drugs, 12 varieties were launched in October as newly registered classified generic drugs, and the first was deemed to have passed the consistency evaluation, and 3 ...
According to the CDE official website, two new traditional Chinese medicines have obtained implicit permission for clinical trials. They are the Category 2.3 new drug “Xuesaitong Soft Capsules” from China Resources Shenghuo and the Category 1.1 new drug “Jiuwei Zhengxiao” from the Institute of Clinical Basic Medicine of the China Academy of Chinese Medical Sciences. Particles”. Xuesaitong soft capsule: carotid atherosclerosis Xuesaitong soft capsule has the functions of activating blood circulation, removing blood stasis, unblocking meridians and activating meridians, and its main component is total saponins of Panax notoginseng. Currently, this drug has been approved for use in the meridian recovery period of ischemic stroke (cerebral infarction) caused by blood stasis blockage. Symptoms include hemiplegia, numbness on one side of the body, crooked mouth and tongue, and slurred speech. This time, China Resources Shenghuo’s Class 2.3 new Chinese medicine “Xuesetong Soft Capsule” has obtained another implied clinical trial license, which ...
Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has received a severe warning from shareholders due to its poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared that if the company’s performance cannot be improved, Deepak Nath will be dismissed and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not yet “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Century-old enterprise faces crisis Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and ...
On the evening of November 12, BeiGene released its third quarter 2024 U.S. stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. The overall performance is eye-catching . In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continue to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. According to the U.S. stock financial report, BeiGene’s financial situation continues to improve, with ...
On November 13, 2024, Lilly announced the latest follow-up data of Phase III clinical SURBOUNT-1 of Tilpolide in the treatment of pre diabetes patients with obesity or overweight. The follow-up time was up to 3 years (176 weeks), and the data were also published in the New England Medical Journal. After 176 weeks of treatment, the proportion of patients who progressed to type 2 diabetes in the Tilpodide treatment group and the placebo control group was 1.2% and 12.6% respectively, and the risk of progression to type 2 diabetes was reduced by 94%. After 17 weeks of drug withdrawal, the rates of progression to type 2 diabetes were 2.4% and 13.7%, respectively, and the risk of progression to type 2 diabetes was reduced by 88%. After drug withdrawal, the proportion of patients who progressed to type 2 diabetes increased rapidly, indicating that the disease progression was delayed but may not ...
Recently (November 7th), the official website of the China National Center for Drug Evaluation (CDE) showed that Chengdu Yuandong Biopharmaceutical Co., Ltd.’s application for the marketing of injection grade naprolimus mesylate, classified as Class 3, has been accepted. According to public information, the indications of this product are for the treatment of acute pancreatitis, chronic pancreatitis with acute exacerbation, postoperative acute pancreatitis, acute pancreatitis after pancreatography, and acute traumatic pancreatitis; Used for the treatment of disseminated intravascular coagulation (DIC); 3. Used to prevent blood clotting during extracorporeal circulation. Naprolimus mesylate is a strong and broad-spectrum serine protease inhibitor. This product was first launched in Japan for the prevention and treatment of disseminated intravascular coagulation (DIC), improvement of acute symptoms of pancreatitis, and anticoagulation during extracorporeal circulation. In March 2020, according to overseas media reports, Professor Junichiro Inoue of the Medical Research Institute of the University of Tokyo and others issued ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.